Canada markets close in 5 hours 42 minutes

SAB Biotherapeutics, Inc. (SABSW)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.04400.0000 (0.00%)
As of 04:00PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.0440
Open0.0410
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0440 - 0.0440
52 Week Range0.0440 - 0.0440
Volume64,300
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)0.80
PE Ratio (TTM)0.15
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

    MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Jay Skyler, MD, MACP, FRCP has been appointed to the company’s Board of Directors. “Dr. Skyler’s appointment to our Board of Directors is a major milestone for SAB,” said Samuel J

  • GlobeNewswire

    SAB Biotherapeutics Provides SAB-142 Trial Update

    MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA disclosed that SAB has completed dosing the third cohort for SAB-142 with no observation of ser

  • GlobeNewswire

    SAB Biotherapeutics to Present at INNODIA Annual Meeting

    MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA will share an overview of the SAB-142 clinical development plan and anticipated milestones at t